1.42Open1.42Pre Close0 Volume150 Open Interest15.00Strike Price0.00Turnover79.94%IV-2.49%PremiumOct 18, 2024Expiry Date1.75Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7389Delta0.1465Gamma6.46Leverage Ratio-0.0211Theta-0.0044Rho-4.78Eff Leverage0.0091Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet